NAD+
Nicotinamide adenine dinucleotide
Overview
NAD+ (Nicotinamide Adenine Dinucleotide, oxidized form) is a fundamental coenzyme involved in cellular redox reactions, sirtuin-mediated deacetylation, PARP-mediated DNA damage response, and CD38-mediated calcium signaling. NAD+ levels decline with age across mammalian tissues, and the restoration or boosting of NAD+ is the central thesis of the contemporary longevity-research field, driving extensive interest in NAD+ precursors (NMN, NR) and direct-IV NAD+ supplementation in both research and med-spa contexts. NAD+ is not a peptide but is included in the catalog because of its frequent co-administration alongside peptide research products and its established role in cellular-energy-metabolism workflows. Lyochem supplies NAD+ at ≥99.0% HPLC purity in lyophilized form. The large fill sizes (100, 500, 1000 mg) reflect the gram-scale dosing typical for IV-infusion preparations and med-spa workflows rather than the μg-mg scales of peptide research products. The analytical packet covers RP-HPLC, UV-Vis absorbance at 260 nm (the diagnostic adenine wavelength), and residual-solvent profiling. Storage at -20 °C protected from light extends the lyophilized shelf life; once reconstituted, NAD+ solutions should be used promptly because the molecule is moisture- and oxidation-sensitive in solution.
Who buys this, and why
Mitochondrial-targeted peptides — MOTS-c, SS-31 (Elamipretide) — and the mitochondrial-targeting small-molecule reagents (NAD+, AICAR, 5-Amino-1MQ, SLU-PP-332) ship to research labs studying OXPHOS, ROS biology, sirtuin-mediated deacetylation, and mitochondrial dysfunction in disease models. The lipophilic / cationic character that drives mitochondrial accumulation also makes some peptides oxidation-prone in solution; working stocks should be prepared fresh or held at −80 °C when the workflow permits.
Primary buyer fit: research laboratories that have validated this peptide into their workflow, research groups studying topical / aesthetic-pharmacology applications, and academic and contract research laboratories.
Specifications
- CAS
- 53-84-9
- Purity (HPLC)
- ≥ 99.0%
- Common vial sizes
- 100 mg, 500 mg, 1000 mg
- MOQ
- On request
- Lead time
- 7–14 days
- Storage
- -20°C, protect from light
Documentation available on request
- Lot-specific Certificate of Analysis (CoA)
- RP-HPLC chromatogram with peak integration
- ESI-MS identity confirmation (±0.5 Da)
- Sequence verification by LC-MS/MS
- Water content by Karl Fischer
- SDS / MSDS
- Oxidative-stability series in solution
- Bacterial endotoxin (LAL) on request
- −80 °C working-stock handling guidance
Regulatory note
Sold for Research Use Only under the receiving laboratory's institutional and jurisdictional regulations. Not a finished dosage form and not labelled for human administration. Working stocks of cationic mitochondrial peptides (SS-31 in particular) should be prepared fresh or held at −80 °C when the workflow permits.
Frequently asked questions
Is NAD+ a peptide, and how should it be handled differently from peptide products?▾
NAD+ is not a peptide, it is a dinucleotide coenzyme consisting of nicotinamide mononucleotide linked to adenosine monophosphate through a pyrophosphate bridge. We include it in the catalog because NAD+ is frequently co-administered alongside peptide research products in longevity-research and med-spa workflows. The handling differs from peptides in two main ways: (1) the analytical methods are HPLC plus UV-Vis at 260 nm (the adenine absorbance) rather than the peptide-focused HPLC + mass spec + sequence verification, and (2) NAD+ in solution is more sensitive to moisture-driven hydrolysis than lyophilized peptides, so reconstituted solutions should be used promptly rather than stored as working stocks.
What's the difference between NAD+, NMN, and NR as longevity-research substrates?▾
All three feed into the same NAD+ salvage pathway but at different entry points. NMN (Nicotinamide Mononucleotide) is the immediate biosynthetic precursor to NAD+; NR (Nicotinamide Riboside) is converted to NMN and then to NAD+; direct NAD+ supplementation bypasses both precursor steps. The trade-off across the three is dosing convenience versus bioavailability: oral NR has the best oral bioavailability; oral NMN is somewhat poorer but commercially established; direct IV NAD+ has the most rapid systemic effect but requires injection. The choice for research depends on which level of the salvage pathway the experimental question targets.
Why do NAD+ med-spa preparations use such large fill sizes (500 mg, 1 g)?▾
NAD+ is dosed at gram-scale rather than the μg-mg scale typical of peptide therapeutics. A standard IV-infusion protocol delivers 250-1000 mg of NAD+ per session, sometimes higher in extended-infusion protocols. The large fill sizes (500 mg, 1000 mg lyophilized) reflect this clinical use case and minimize the number of vials needed per infusion preparation. Med-spa providers typically reconstitute one fill into a saline IV bag for the procedure. Research-lab buyers using NAD+ in cell-culture or biochemical-assay work can use a fraction of the 100 mg fill and store the remainder sealed under nitrogen at -20 °C.